NAT10 Antibody

Code CSB-PA863939LA01HU
Size US$166
Order now
Image
  • IHC image of CSB-PA863939LA01HU diluted at 1:300 and staining in paraffin-embedded human pancreatic cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-PA863939LA01HU diluted at 1:300 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunoprecipitating NAT10 in Hela whole cell lysate
    Lane 1: Rabbit control IgG instead of CSB-PA863939LA01HU in Hela whole cell lysate. For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000)
    Lane 2: CSB-PA863939LA01HU (6μg) + Hela whole cell lysate (1mg)
    Lane 3: Hela whole cell lysate (20μg)

  • Western Blot
    Positive WB detected in: Hela whole cell lysate
    All lanes:NAT10 antibody at 7μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 116, 108 kDa
    Observed band size: 116 kDa

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) NAT10 Polyclonal antibody
Uniprot No.
Target Names
NAT10
Alternative Names
ALP antibody; DKFZp434C116 antibody; FLJ10774 antibody; FLJ12179 antibody; FLJ23850 antibody; hALP antibody; KIAA1709 antibody; N acetyltransferase 10 antibody; N acetyltransferase 10 GCN5 related antibody; N acetyltransferase like antibody; N acetyltransferase like protein antibody; N-acetyltransferase 10 antibody; NAT10 antibody; NAT10_HUMAN antibody; NET43 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human RNA cytidine acetyltransferase protein (909-1025AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The NAT10 Antibody (Product code: CSB-PA863939LA01HU) is Non-conjugated. For NAT10 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA863939LB01HU NAT10 Antibody, HRP conjugated ELISA
FITC CSB-PA863939LC01HU NAT10 Antibody, FITC conjugated
Biotin CSB-PA863939LD01HU NAT10 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, WB, IHC, IP
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:200-1:500
IP 1:200-1:2000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
RNA cytidine acetyltransferase that catalyzes the formation of N(4)-acetylcytidine (ac4C) modification on mRNAs, 18S rRNA and tRNAs. Catalyzes ac4C modification of a broad range of mRNAs, enhancing mRNA stability and translation. mRNA ac4C modification is frequently present within wobble cytidine sites and promotes translation efficiency. Mediates the formation of ac4C at position 1842 in 18S rRNA. May also catalyze the formation of ac4C at position 1337 in 18S rRNA. Required for early nucleolar cleavages of precursor rRNA at sites A0, A1 and A2 during 18S rRNA synthesis. Catalyzes the formation of ac4C in serine and leucine tRNAs. Requires the tRNA-binding adapter protein THUMPD1 for full tRNA acetyltransferase activity but not for 18S rRNA acetylation. In addition to RNA acetyltransferase activity, also able to acetylate lysine residues of proteins, such as histones, microtubules, p53/TP53 and MDM2, in vitro. The relevance of the protein lysine acetyltransferase activity is however unsure in vivo. Activates telomerase activity by stimulating the transcription of TERT, and may also regulate telomerase function by affecting the balance of telomerase subunit assembly, disassembly, and localization. Involved in the regulation of centrosome duplication by acetylating CENATAC during mitosis, promoting SASS6 proteasome degradation.
Gene References into Functions
  1. immunohistochemistry staining of NAT10 in hepatocellular carcinoma tissues demonstrates that the cytoplasmic NAT10 is correlated with poorer prognosis compared with nuclear NAT10, while the membranous NAT10 predicts the poorest clinical outcome of the patients. PMID: 29634924
  2. Increased NAT10 expression levels are associated with shortened hepatocellular carcinoma (HCC) patient survival and correlated with mutant p53 levels. NAT10 upregulates mutant p53 level and might enhance its tumorigenic activity. Hence, it is proposed that NAT10 could be a potential prognostic and therapeutic candidate for p53-mutated HCC. PMID: 28859621
  3. NAT10 is acetylated in vivo and autoacetylated in vitro PMID: 27993683
  4. NAT10 translocates to nucleoplasm to bind and acetylate p53 at K120 upon cellular stress. PMID: 26882543
  5. The subcellular redistribution of NAT10 can be induced by decreases in GSK-3b activity. This redistribution increases cancer cell motility, and is, thus, correlated with invasive potential and poorer clinical outcome PMID: 24982245
  6. Identification of NAT10 as responsible for both 18S rRNA and leucine/serine tRNA acetylation. PMID: 25653167
  7. NAT10 is an ATP-dependent RNA acetyltransferase responsible for formation of N(4)-acetylcytidine (ac(4)C) at position 1842 in the terminal helix of mammalian 18 S rRNA. PMID: 25411247
  8. we identified hALP, a histone acetyl-transferase as a novel t-UTP PMID: 21177859
  9. hALP is a nucleolar protein, and the nucleolar localization is mediated by its carboxy terminal domain. PMID: 18677378
  10. The investigation suggested that hALP influences the activity of histone acetylation and could up-regulate telomerase activity through transactivation of hTERT promoter. PMID: 14592445
  11. The above results suggested that NAT10 could be involved in DNA damage response and increased cellular resistance to genotoxicity. PMID: 17180247
  12. chromosome de-condensation needs the function of an inner nuclear membrane (INM) protein hsSUN1 and a membrane-associated histone acetyltransferase (HAT), hALP. PMID: 17631499
  13. NAT10 may play an important role in cell division through facilitating reformation of the nucleolus and midbody in the late phase of cell mitosis, and stabilization of microtubules. PMID: 19303003

Show More

Hide All

Subcellular Location
Nucleus, nucleolus. Midbody.
Protein Families
RNA cytidine acetyltransferase family, NAT10 subfamily
Database Links

HGNC: 29830

OMIM: 609221

KEGG: hsa:55226

STRING: 9606.ENSP00000257829

UniGene: Hs.577281

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*